Research and Clinical Trial Cancer Consortium Initiative; established, report.

Membership composition changed from nine members to twelve members, adding three nonacademic health systems to the list of institutional representatives.

Secretary of Health and Human Resources added as an ex officio member with voting privileges.

Removed specific mention of Inova Schar Cancer Institute and replaced it with a general provision for three nonacademic health systems in the institutional representation list.

Formatting and layout changes including removal of date headers, addition of House substitute markings, and improved text alignment throughout the document.

Date references updated from placeholder format to specific date (February 13, 2025) in the House substitute version.

Page numbering and bill identification numbers were added or adjusted to reflect House substitute formatting standards.

Total membership reduced from twelve members to nine members

Removed the ex officio Secretary of Health and Human Resources member with voting privileges

Changed institutional representation to include Inova Schar Cancer Institute instead of three nonacademic health systems

Reduced institutional representatives from six to six (replacing three nonacademic health systems with one specific institution)

Three nonacademic health systems were added as institutional representatives, increasing total membership from nine to twelve members.

The Secretary of Health and Human Resources was added as an ex officio member with voting privileges.

Initial appointment terms for nonlegislative citizen members were staggered to three, two, and one year terms instead of the original uniform terms.

Added Inova Schar Cancer Institute as a sixth institutional member to the Research and Clinical Trial Cancer Consortium Initiative, increasing total membership from eight to nine members.

Removed the sunset provision that would have required the bill to be reenacted during the 2026 Session, making the initiative permanent.

Updated membership requirements to reflect the new nine-member structure with six institutional representatives and three citizen members.

Added Tech Carilion to the list of institutions participating in the Research and Clinical Trial Cancer Consortium Initiative, expanding the consortium's reach and resources.

Updated formatting and layout of the bill document to reflect its engrossed status with proper spacing and section numbering.